Free tool
FAERS Monitor: Radicava Ors
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 215446 or its brand name (Radicava Ors, Edaravone). Reports on generic versions are filed under their own applications.
Reports
1,604
Serious
1,191
74% of reports
Hospitalization
407
Death reported
462
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death212
- cerebral infarction99
- amyotrophic lateral sclerosis84
- disease progression74
- drug ineffective63
- off label use53
- dyspnoea51
- muscular weakness50
- fatigue45
- pneumonia45
- diarrhoea44
- condition aggravated41
- asthenia38
- nausea34
- gait disturbance33
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 3 |
| 2005 | 3 |
| 2006 | 4 |
| 2007 | 3 |
| 2008 | 2 |
| 2009 | 4 |
| 2010 | 1 |
| 2011 | 3 |
| 2012 | 30 |
| 2013 | 25 |
| 2014 | 18 |
| 2015 | 22 |
| 2016 | 21 |
| 2017 | 45 |
| 2018 | 49 |
| 2019 | 76 |
| 2020 | 42 |
| 2021 | 56 |
| 2022 | 103 |
| 2023 | 194 |
| 2024 | 363 |
| 2025 | 319 |
| 2026 | 218 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,555 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| amyotrophic lateral sclerosisSignal | 84 | 532.1 | 430.2 | 42,289 |
| cerebral infarctionSignal | 99 | 53.3 | 44.1 | 5,018 |
| disease progressionSignal | 74 | 8.2 | 6.6 | 463 |
| muscular weaknessSignal | 50 | 5.8 | 4.4 | 193 |
| deathSignal | 212 | 3.2 | 2.8 | 337 |
| gait disturbanceSignal | 33 | 2.3 | 1.6 | 22 |
| pneumonia | 45 | 1.8 | 1.4 | 16 |
| condition aggravated | 41 | 1.8 | 1.3 | 13 |
| asthenia | 38 | 1.3 | 1.0 | 3 |
| dyspnoea | 51 | 1.2 | 0.9 | 1 |
| diarrhoea | 44 | 0.9 | 0.7 | 0 |
| off label use | 53 | 0.8 | 0.6 | 3 |
| fatigue | 45 | 0.8 | 0.6 | 3 |
| drug ineffective | 63 | 0.6 | 0.5 | 15 |
| nausea | 34 | 0.6 | 0.4 | 12 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.